Jason Rubin Joins Incyte Genomics as Executive Vice President of Corporate Affairs Palo Alto, CA – October 9, 2002 – Incyte Genomics, Inc. (Nasdaq: INCY) announced today that Jason Rubin, 44, has joined the company as executive vice president of corporate affairs, a new position. Mr. Rubin is responsible for leading Incyte's investor and public relations, employee and marketing communications, Internet communications, public policy and community affairs activities. Rubin is based at the company's drug discovery facility in Newark, Delaware and reports to chief executive officer Paul Friedman, M.D. Before establishing his own communications consulting firm in 1999, Mr. Rubin was vice president of corporate communications at Centocor, Inc., Cephalon, Inc. and Immunex Corporation. Previously, he served as director of the biotechnology practice at Hill and Knowlton Public Affairs in Washington, D.C. "We welcome Jason's insights, counsel and guidance in communicating our progress as we expand our drug discovery efforts, continue our genomic database development programs and work to build shareholder value," Friedman said. Mr. Rubin holds a master of science degree in management from M.I.T.'s Sloan School of Management and a bachelor of arts degree in geology from Middlebury College. He is a member of the National Investor Relations Institute and a frequent speaker on communications practices in the biotechnology industry. Incyte Genomics, Inc., has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode. Incyte is leveraging its leading intellectual property and genomic information position to be a leader in discovering and developing therapeutic small molecules, secreted proteins and antibodies. In addition, Incyte has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and licenses pharmaceutically relevant intellectual property. These offerings facilitate pharmaceutical and biotechnology researchers in their drug discovery and development; including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the expansion and continuation of Incyte programs; the ability of Incyte's products and services to enhance the research efforts of its customers and Incyte's ability to leverage its intellectual property position to become a leader in the discovery and development of therapeutic small molecules, secreted proteins and antibodies, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the impact of competition and alternative technologies, processes and approaches on Incyte's business; Incyte's ability to compete against competitors that may have greater financial or other resources; changes in consumer demand for Incyte's products and services; economic factors that may impact Incyte's business; changes in Incyte's business plan; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; changes in patent laws; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report Form 10-Q for the Quarter ended June 30, 2002. Incyte disclaims any intent or obligation to update these forward-looking statements.